EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

被引：1
|
作者：
Powles, Thomas
van der Heijden, Michiel Simon
Loriot, Yohann
Bedke, Jens
Valderrama, Begona P.
Iyer, Gopa
Kikuchi, Eiji
Hoffman-Censits, Jeannie
Vulsteke, Christof
Drakaki, Alexandra
Rausch, Steffen
Arafat, Waddah
Park, Se Hoon
Swami, Umang
Li, Jian-Ri
Gorla, Seema Rao
Homet Moreno, Blanca
Yu, Xuesong
Lu, Yi-Tsung
Gupta, Shilpa
机构：
[1] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, London, England
[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France
[4] Univ Paris Saclay, Dept Essais Precoces, Villejuif, France
[5] Klinikum Stuttgart, Dept Urol, Stuttgart, Germany
[6] Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany
[7] Hosp Univ Virgen del Rocio, Seville, Spain
[8] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, New York, NY USA
[9] St Marianna Univ, Dept Urol, Sch Med, Kawasaki, Kanagawa, Japan
[10] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[11] Maria Middelares Hosp, Dept Med Oncol, Antwerp, Belgium
[12] Univ Calif Los Angeles, Los Angeles, CA USA
[13] Eberhard Karls Univ Tubingen, Dept Urol, Tubingen, Germany
[14] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[15] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[16] Univ Utah, Dept Med, Huntsman Canc Inst, Salt Lake City, UT USA
[17] Taichung Vet Gen Hosp, Dept Surg, Div Urol, Taichung, Taiwan
[18] Astellas Pharma Inc, Northbrook, IL USA
[19] Merck & Co Inc, Rahway, NJ USA
[20] Pfizer Inc, Bothell, WA USA
[21] Cleveland Clin, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.664
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
    Mar, Nataliya
    Friedlander, Terence W.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Bilen, Mehmet Asim
    Balar, Arjun Vasant
    Henry, Elizabeth
    Srinivas, Sandy
    Rosenberg, Jonathan E.
    Petrylak, Daniel Peter
    Burgess, Earle Frederick
    Merchan, Jaime R.
    Tagawa, Scott T.
    Carret, Anne-Sophie
    Steinberg, Joyce Leta
    Chaney, Marya F.
    Milowsky, Matthew, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
    Matsubara, Nobuaki
    Yonese, Junji
    Kojima, Takahiro
    Azuma, Haruhito
    Matsumoto, Hiroaki
    Powles, Thomas
    Rosenberg, Jonathan E.
    Petrylak, Daniel P.
    Matsangou, Maria
    Wu, Chunzhang
    Campbell, Mary
    Yamashiro, Mayumi
    CANCER MEDICINE, 2023, 12 (03): : 2761 - 2771
  • [33] Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.
    Friedlander, Terence W.
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Petrylak, Daniel P.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Mar, Nataliya
    Moon, Helen H.
    McKay, Rana R.
    Bilen, Mehmet Asim
    Borchiellini, Delphine
    Iafolla, Marco
    Carret, Anne-Sophie
    Yu, Yao
    Guseva, Maria
    Kataria, Ritesh S.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)
    Galsky, Matt D.
    Grande, Enrique
    Necchi, Andrea
    Drakaki, Alexandra
    Loriot, Yohann
    Franco, Sonia
    Ichimaru, Mari
    Zhang, Wei
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.
    Mamtani, Ronac
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Valderrama, Begona P.
    Gurney, Howard
    Bedke, Jens
    Van der Heijden, Michiel Simon
    Wu, Chunzhang
    Hepp, Zsolt
    McKay, Caroline
    Petrylak, Daniel P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results
    Funt, Samuel A.
    Grivas, Petros
    Gao, Xin
    Vaena, Daniel A.
    Zhang, Tian
    Milowsky, Matthew I.
    Rao, Mayank
    Liu, Harry
    Tipton, Kimberly
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Randolph, Sophia
    Tsiatis, Athanasios C.
    Jain, Rohit K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Hoimes, Christopher J.
    Petrylak, Daniel P.
    Flaig, Thomas W.
    Moon, Helen H.
    Friedlander, Terence W.
    Mar, Nataliya
    McKay, Rana R.
    Srinivas, Sandy
    Gravis, Gwenaelle
    Ramamurthy, Chethan
    Bupathi, Manojkumar
    Bracarda, Sergio
    Wright, Phoebe
    Carret, Anne-Sophie
    Yu, Yao
    Matsuda, Tara
    Kataria, Ritesh S.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naive UC (DAD-IO)
    McGregor, Bradley Alexander
    Kwak, Lucia
    Sonpavde, Guru P.
    Berg, Stephanie A.
    Choueiri, Toni K.
    Bellmunt, Joaquim
    Mantia, Charlene
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] EV-301 Long-Term Outcomes: 24-Month Findings From Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy in Previously Treated Advanced Urothelial Carcinoma
    Rosenberg, J.
    Powles, T.
    Sonpavde, G.
    Loriot, Y.
    Duran, I.
    Lee, J.
    Matsubara, N.
    Vulsteke, C.
    Castellano, D.
    Mamtani, R.
    Wu, C.
    Matsangou, M.
    Campbell, M.
    Petrylak, D.
    Cathomas, R.
    SWISS MEDICAL WEEKLY, 2022, 152 : 16S - 17S
  • [40] Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy
    Rosenberg, Jonathan E.
    Mamtani, Ronac
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Gurney, Howard
    Bedke, Jens
    van der Heijden, Michiel S.
    Galli, Luca
    Keam, Bhumsuk
    Masumori, Naoya
    Meran, Johannes
    O'Donnell, Peter H.
    Park, Se Hoon
    Grande, Enrique
    Sengelov, Lisa
    Uemura, Hiroji
    Skaltsa, Konstantina
    Campbell, Mary
    Matsangou, Maria
    Wu, Chunzhang
    Hepp, Zsolt
    Mckay, Caroline
    Powles, Thomas
    Petrylak, Daniel P.
    EUROPEAN UROLOGY, 2024, 85 (06) : 574 - 585
12345